Trends in Persons Prescribed HIV Postexposure Prophylaxis in the United States, 2015–2023
Our analysis found an increasing trend in PEP use annually, possibly reflecting greater PEP awareness and broader HIV prevention efforts. Increased use of a bictegravir-based PEP regimen in 2023 suggests a shift in PEP prescribing practices, likely due to its once-daily dosing and high tolerability. Our findings can guide future recommendations for PEP medications.
Authors
- Weiming Zhu (ORCID: https://orcid.org/0000-0002-9042-6202)
- Karen W. Hoover (ORCID: https://orcid.org/0000-0003-4942-7905)
- Athena P. Kourtis (ORCID: https://orcid.org/0000-0003-1585-1310)
- Jesse O’Shea (ORCID: https://orcid.org/0000-0001-7292-8834)
- Mary R. Tanner (ORCID: https://orcid.org/0000-0002-2755-1123)
- Laura M. Mann (ORCID: https://orcid.org/0000-0003-1302-2711)
- Su‐Huai Wei (ORCID: https://orcid.org/0000-0003-1563-4738)
- Ya-Lin A. Huang (ORCID: https://orcid.org/0000-0003-3137-8594)
- J. Le (ORCID: https://orcid.org/0000-0001-8702-933X)
Institutions
- Centers for Disease Control and Prevention (US)
- National Center for HIV/AIDS Viral Hepatitis STD and TB Prevention (US)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2025-10-16
- DOI
- https://doi.org/10.1093/cid/ciaf581
- Primary Topic
- HIV/AIDS Research and Interventions
- Type
- article
- Field-Weighted Citation Impact
- 0.00